 This study found that introducing new TB vaccines could significantly reduce income-based inequality in the health and household economic outcomes of TB in low-income and middle-income countries. Specifically, the poorest two-income quintiles would benefit most from the introduction of these vaccines, with the poorest quintile benefiting the most. The study also found that the introduction of these vaccines could prevent up to $6.5 billion worth of patient-incurred total costs and up to $22.9 million households from facing catastrophic costs. This article was authored by Mark J.I.T., Richard G. White, Nicholas A. Menzies, and others.